Interleukin-1 blocking agents for treating COVID-19 (search done on 5 November 2021)

Added February 17, 2022

Citation: Davidson M, Menon S, Chaimani A, et al. Interleukin-1 blocking agents for treating COVID-19. Cochrane Database of Systematic Reviews. 2022;(1):CD015308.

Language: Abstract available in EN / ES / FA / FR / ZA; Plain language summary available in EN / ES / FA / FR / ZA; Full text available in EN; Podcast available in EN / FR.

Free to view: Yes.

What is this? Interleukin-1 blocking agents have been suggested as possible treatments for COVID-19 patients.

In this Cochrane rapid living review, the authors searched for randomized trials of interleukin-1 blocking agents for treating COVID-19 patients. They did not restrict their searches by language of publication and did the most recent search on 5 November 2021. They included 4 trials of anakinra and 2 trials of canakinumab, and identified a further 16 registered trials with no results available at the time of this version of the review.

What was found: At the time of this version of this living review, there was insufficient evidence to show that medicines that block interleukin‐1 are effective for treating COVID-19 patients.

 

This summary was prepared by, edited by, and finalised by Mike Clarke.

الإنكار 免责声明 免責聲明 Disclaimer Clause de non-responsabilité Haftungsausschluss Disclaimer 免責事項 Aviso legal Exención de responsabilidad

Share